Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02845297
Title Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

acute myeloid leukemia

Therapies

Azacitidine + Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.